Effect of the Combination of varsartan with HCTZ on circadian BP rhythm
- Conditions
- Chronic Kidney Disease (CKD)
- Registration Number
- JPRN-UMIN000005601
- Lead Sponsor
- Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
- Brief Summary
Of the 25 eligible patients, one had excess BP reduction during add-on HCTZ therapy and another was judged as excessive urine collection, and they were excluded from the study. Lower Na balance was produced by add-on HCTZ to ARB treatment without an increase of intrarenal renin-angiotensin system activity, leading to restoration of nocturnal hypertension. J Renin Angiotensin Aldosterone Syst. 2016 Jun 9;17(2):1470320316652032
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1. previous treatment with ARB, other than valsartan, or diuretics 2 months before enrollment 2. contraindication to valsartan or HCTZ (history of allergic reaction to them, bilateral renal artery stenosis) 3. presence or possibility of pregnancy 4. HbA1c 9.0 or more % 5. GOT >100, or GPT >85 6. endocrine hypertension 7. accelerated o r malignant hypertension (progressive renal dysfunction with diastolic BP of >120-130 mmHg 8. serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases 9. nephrotic syndrome (serum albumin <2.5 g/dl) 10. patients under hemodialysis therapy 11. any reason for ineligibility suggested by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in the night/day ratio ofmean arterial pressure (MAP)
- Secondary Outcome Measures
Name Time Method office BP, night/day ratios of natriuresis and albuminuria, urinary angiotensinogen excretion rate, plasma catecholamines